Press Releases

Click on the year below to view news articles and press releases

2012

Programme to overcome major hurdle in stabilisation of cells starts 1 February
31/1/2012
Stabilitech Ltd's Regenerative Medicine Technology programme (“RegenMed”) to address the major problem of the stabilisation of cells.

2011

Stabilitech raises £2.2 million to drive expansion of business and maximise potential of innovative technology platform
12/5/2011
The funding will be used to progress the commercialision of its cutting edge proprietary thermal stabilisation technology platform
Stabilitech appoints new Commercial Director
5/2/2011
Stabilitech announced the appointment of Donna Hackett as Commercial Director
Stabilitech participates in Future Health Mission and gives radio interview with TechNation
2/2/2011
Stabilitech Ltd, the stabilisation company, has recently returned from participating in the Future Health Mission to the United States

2010

Stabilitech is awarded Technology Strategy Board grant
24/8/2010
Stabilitech Ltd (London) announced today that is has been awarded a grant by the Technology Strategy Board as part of its competition on Detection and Identification of Infectious Agents: Fighting Infection through Detection.
Stabilitech signs $4 million contract with Defense Threat Reduction Agency
24/8/2010
Stabilitech Ltd, the protein stabilisation company, announced today that it has signed a contract with the United States Defense Threat Reduction Agency (DTRA),

2009

Stabilitech appoints new Development Director
27/10/2009
Dr Stephen Ward has joined Stabilitech as Development Director, a newly created position as the company expands and enters its next phase.
Stabilitech secures £3.3 million Equity Funding
12/3/2009
Stabilitech Ltd, a private company developing proprietary thermal stabilisation technologies for the vaccine and biopharmaceutical markets, is pleased to announce today that it has successfully raised £3.3 million of equity finance from new and existing investors, including business angels and high net worth individuals.
Stabilitech appoints new Non-Executive Director
19/2/2009
Stabilitech is very pleased to announce that Dr Peter Cozens has recently joined Stabilitech’s Board as non-executive director. Peter has worked for more than 30 years in the pharmaceutical industry, with broad international experience in both the biotechnology and conventional pharmaceutical sectors of the industry.

2008

Stabilitech wins LTF Environment Award
31/10/2008
Stabilitech is Winner of the Environment Award in London Technology Fund Competition 2008 Stabilitech’s technology protects efficacy, reduces wastage and saves energy.

2007

Stabilitech appoints new CEO
20/11/2007
Dr Barbara Domayne-Hayman has joined Stabilitech as CEO. Barbara was previously Commercial Director at Arrow Therapeutics prior to their acquisition by AstraZeneca.